Bell Asset Management Ltd decreased its stake in Cencora, Inc. (NYSE:COR - Free Report) by 25.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 34,716 shares of the company's stock after selling 11,565 shares during the period. Cencora accounts for about 1.4% of Bell Asset Management Ltd's holdings, making the stock its 17th biggest position. Bell Asset Management Ltd's holdings in Cencora were worth $7,800,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in COR. JFS Wealth Advisors LLC raised its stake in Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after acquiring an additional 46 shares during the period. SBI Securities Co. Ltd. bought a new stake in shares of Cencora in the fourth quarter valued at approximately $30,000. Householder Group Estate & Retirement Specialist LLC lifted its stake in shares of Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after buying an additional 69 shares in the last quarter. Kentucky Trust Co bought a new position in Cencora in the 4th quarter worth approximately $33,000. Finally, WASHINGTON TRUST Co grew its stake in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after buying an additional 46 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Cencora
In related news, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. The trade was a 24.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Chairman Steven H. Collis sold 14,578 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the sale, the chairman now owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. This trade represents a 4.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,675 shares of company stock valued at $8,034,778 in the last three months. Company insiders own 10.80% of the company's stock.
Cencora Price Performance
Shares of COR stock traded up $5.31 during mid-day trading on Friday, hitting $284.46. The company had a trading volume of 1,509,188 shares, compared to its average volume of 1,506,610. The company has a market capitalization of $55.16 billion, a P/E ratio of 40.46, a P/E/G ratio of 1.31 and a beta of 0.55. The stock's 50 day moving average price is $260.27 and its 200-day moving average price is $245.01. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $296.65. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.
Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.
Cencora Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio is currently 31.29%.
Analysts Set New Price Targets
A number of research firms have weighed in on COR. JPMorgan Chase & Co. lifted their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Bank of America boosted their price objective on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday. StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Wells Fargo & Company boosted their price target on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. Finally, Evercore ISI increased their price objective on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Cencora has an average rating of "Moderate Buy" and a consensus target price of $284.20.
Check Out Our Latest Stock Analysis on COR
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Read More
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
